- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05980000
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)
January 27, 2024 updated by: Washington University School of Medicine
Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)
This is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy.
Ramucirumab is a VEGFR-2 inhibitor believed to potentially enhance the efficacy of PD-1 inhibitors such as pembrolizumab.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
72
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Douglas R Adkins, M.D.
- Phone Number: 314-747-8475
- Email: dadkins@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Douglas R Adkins, M.D.
- Phone Number: 314-747-8475
- Email: dadkins@wustl.edu
-
Principal Investigator:
- Douglas R Adkins, M.D.
-
Sub-Investigator:
- Peter Oppelt, M.D.
-
Sub-Investigator:
- Esther Lu, Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Incurable RM-HNSCC, defined as RM disease or second or subsequent primary HNSCC not amenable to cure by surgery and/or radiation therapy or patient declines or is ineligible for curative therapy. Eligible primary tumor sub-sites include oral cavity, oropharynx, larynx and hypopharynx only.
- PD-L1 positive (CPS ≥1) disease, based on local IHC assay using 22C3 antibody.
- Measurable disease per RECIST 1.1.
- No prior systemic therapy for RM-HNSCC. RM disease developing within 6 months of completion of either a) systemic platinum or cetuximab therapy given as a component of a curative-intent multi-modality regimen or b) radiation therapy and/or surgery is eligible.
- At least 18 years of age.
- ECOG performance status 0-1.
Normal bone marrow and organ function as defined below:
- Absolute neutrophil count ≥ 1.5 K/cumm
- Platelets ≥ 100 K/cumm
- Hemoglobin ≥ 9.0 g/dL
- Total bilirubin ≤ 1.5 x IULN
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN. In the setting of liver metastases, AST(SGOT)/ALT(SGPT) ≤ 5.0 x IULN
- Creatinine ≤ 1.5 x ULN. If patient has creatinine > 1.5 x ULN, then 24 hour urine collection must be performed and creatinine clearance must be ≥ 40 mL/min by Cockcroft-Gault
- Urine protein to creatinine ratio (UPC) ≤ 1; if UPC > 1, then a 24-hour urine protein must be assessed and patient must have a 24-hour urine protein value < 1 g to be eligible
- INR ≤ 1.5 (≤ 3.0 if on warfarin) and PTT ≤ 1.5 x ULN (Patients are allowed to be on anticoagulation)
- The effects of Ramucirumab on the developing human fetus are unknown. For this reason and because VEGFR2 inhibiting agents are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 28 days after completion of the study.
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- PD-L1 negative (CPS 0) disease, based on local IHC assay using 22C3 antibody.
- Cutaneous or nasopharynx SCC.
- Major surgery within 28 days prior to C1D1, minor surgery or subcutaneous venous access device placement within 7 days prior to C1D1, history of significant tumor site bleeding within 14 days prior to C1D1, or elective or planned major surgery to be performed during the course of the clinical trial.
- Palliative radiation therapy within 2 weeks of C1D1.
- Serious or non-healing, non-malignant wound, ulcer, or bone fracture within 28 days prior to C1D1.
- A history of other malignancy ≤ 1 year previous with the exception of completely resected skin carcinoma or other cancers with a low risk (<10%) of recurrence over the next 2 years.
- Cirrhosis at a level of Child-Pugh B (or worse). Cirrhosis of any degree with a history of hepatic encephalopathy or clinically meaningful ascites (from cirrhosis requiring diuretics or paracentesis).
- Currently receiving any other investigational agents.
- Ongoing toxicity attributed to prior anti-cancer therapy that is > grade 1, except alopecia, anemia, lymphopenia, xerostomia, fatigue or rash.
- Active central nervous system metastases: defined as currently receiving radiation therapy to metastatic CNS disease. Once radiation therapy is completed and patient has completed a 2 week washout, patients with CNS disease are eligible if they meet all other criteria for enrollment.
- A history of severe allergic reactions attributed to compounds of similar chemical or biologic composition to Ramucirumab or other agents used in the study.
- Serious uncontrolled intercurrent illness within the 3 months prior to study entry including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.
- Receiving systemic corticosteroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of intense immunosuppressive therapy within 7 days prior to C1D1.
- Active autoimmune disease (i.e. rheumatoid arthritis, lupus) that has required IV or subcutaneous systemic treatment in the past 6 months prior to C1D1 (excluding Rituxan). Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- GI perforation or fistula within 6 months of C1D1. Malignant oral fistulas are not excluded.
- History of inflammatory bowel disease, ulcerative colitis, or Crohn's disease.
- Poorly controlled hypertension (defined as serial high blood pressure measurements [systolic blood pressures of > 160 mmHg or diastolic blood pressures of > 100 mmHg] documented during the four-week interval prior to C1D1) despite standard medical management. Initiation or adjustment of antihypertensive medications to control blood pressure is permitted prior to study entry.
- Arterial thromboembolic events (including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina) within 6 months, prior to C1D1.
- Deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") within 3 months prior to C1D1.
- Any bleeding (grade 3 or 4) within 3 months prior to C1D1.
- Receiving chronic antiplatelet therapy, including nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted.
- Current, active bleeding (within 14 days prior to C1D1) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices), if patients are taking an oral anticoagulant or low molecular weight heparin. Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or LMWH prior to C1D1.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to C1D1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: Ramucirumab and Pembrolizumab
Patients receive ramucirumab IV and pembrolizumab IV every 3 weeks.
Cycles are 21 days in length.
Treatment will continue until progression or unacceptable toxicity for up to 35 cycles of treatment.
|
Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.
Other Names:
Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
Other Names:
|
Active Comparator: Arm 2: Pembrolizumab monotherapy
Patients receive pembrolizumab IV every 3 weeks.
Cycles are 21 days in length.
Treatment will continue until progression or unacceptable toxicity for up to 35 cycles of treatment.
|
Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: From start of study treatment through completion of treatment (estimated to be 24 months)
|
ORR is defined as the number of patients with a complete response (CR) and a partial response (PR) by RECIST 1.1 criteria.
A CR is defined as the disappearance of all target lesions, reduction in pathological lymph nodes to <10 mm in short axis, and disappearance of all non-target lesions with normalization of tumor marker level.
A PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
From start of study treatment through completion of treatment (estimated to be 24 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: From start of study treatment through 5 years
|
PFS is defined as the duration of time from the start of treatment to time of progression or death, whichever occurs first.
|
From start of study treatment through 5 years
|
Overall Survival (OS)
Time Frame: From start of study treatment through 5 years
|
OS is defined as the time from start of treatment to the date of death, censored at the last follow-up otherwise.
|
From start of study treatment through 5 years
|
Duration of Response (DoR)
Time Frame: From time criteria is met for CR or PR through completion of treatment (estimated to be 1 year and 40 weeks)
|
Duration of overall response is measured from the time criteria are met for a CR or PR per RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.
Duration of overall CR is measured from the time criteria are met for a CR per RECIST 1.1 until the first date that progressive disease is objectively documented.
|
From time criteria is met for CR or PR through completion of treatment (estimated to be 1 year and 40 weeks)
|
Incidence rate, frequency, and severity of adverse events (AEs)
Time Frame: From start of study treatment through 30 days after last dose (expected to be 2 years and 1 month)
|
AEs will be assessed using CTCAE v4.0 and summarized by arm.
|
From start of study treatment through 30 days after last dose (expected to be 2 years and 1 month)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Douglas R Adkins, M.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 27, 2023
Primary Completion (Estimated)
April 30, 2028
Study Completion (Estimated)
April 30, 2031
Study Registration Dates
First Submitted
July 30, 2023
First Submitted That Met QC Criteria
July 30, 2023
First Posted (Actual)
August 7, 2023
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 27, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Squamous Cell
- Head and Neck Neoplasms
- Carcinoma
- Recurrence
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
- Ramucirumab
Other Study ID Numbers
- 202308161
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Carcinoma
-
Glenn J. HannaImmunityBio, Inc.RecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Carcinoma | Recurrent Skin Carcinoma | Recurrent Salivary Gland Carcinoma | Skin Squamous Cell CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck CarcinomaUnited States
-
Nektar TherapeuticsMerck Sharp & Dohme LLC; SFJ Pharmaceuticals, Inc.TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States, Austria, Greece, Italy
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Carcinoma | Locally Advanced Head and Neck CarcinomaUnited States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLCRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell CarcinomaUnited States
-
BioNTech SERecruitingRecurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck CancerGermany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
-
PCI Biotech ASTerminatedRecurrent Head and Neck Cancer | Carcinoma, Squamous Cell of Head and NeckGermany, United Kingdom, France, Lithuania, Netherlands, Poland
Clinical Trials on Ramucirumab
-
Shanghai Henlius BiotechTerminatedHealthy Male VolunteersChina
-
Yonsei UniversityNot yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedGastric Cancer | Non-small Cell Lung Cancer | Colo-rectal CancerChina
-
Eli Lilly and CompanyParexelCompleted
-
Eli Lilly and CompanyCompleted
-
Yale UniversityWithdrawnTransitional Cell CarcinomaUnited States
-
Eli Lilly and CompanyCompleted
-
Samsung Medical CenterRecruiting
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyCompletedAdult Glioblastoma MultiformeUnited States